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Abstract
Background: To compare the effects of resistance training versus passive physical therapy on bone turnover markers
(BTM) in the metastatic bone during radiation therapy (RT) in patients with spinal bone metastases. Secondly, to
evaluate an association of BTM to local response, skeletal-related events (SRE), and number of metastases.
Methods: In this randomized trial, 60 patients were allocated from September 2011 to March 2013 into one of
the two arms: resistance training (Arm A) or passive physical therapy (Arm B) with thirty patients in each arm
during RT. Biochemical markers such as pyridinoline (PYD), desoxy-pyridinoline (DPD), bone alkaline phosphatase
(BAP), total amino-terminal propeptide of type I collagen (PINP), beta-isomer of carboxy-terminal telopeptide of
type I collagen (CTX-I), and cross-linked N-telopeptide of type I collagen (NTX) were analyzed at baseline, and
three months after RT.
Results: Mean change values of PYD and CTX-I were significantly lower at 3 months after RT (p = 0.035 and p = 0.043)
in Arm A. Importantly, all markers decreased in both arms, except of PYD and CTX-I in arm B, although significance was
not reached for some biomarkers. In arm A, the local response was significantly higher (p = 0.003) and PINP could be
identified as a predictor for survivors (OR 0.968, 95%CI 0.938–0.999, p = 0.043). BAP (OR 0.974, 95%CI 0.950–0.998,
p = 0.034) and PINP (OR 1.025, 95%CI 1.001–1.049, p = 0.044) were related with an avoidance of SRE.
Conclusions: In this group of patients with spinal bone metastases, we were able to show that patients with
guided resistance training of the paravertebral muscles can influence BTM. PYD and CTX-I decreased significantly
in arm A. PINP can be considered as a complementary tool for prediction of local response, and PINP as well as
BAP for avoidance of SRE.
Trial registration: Clinical trial identifier NCT 01409720. August 2, 2011.
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Background
Spinal bone metastases represent the most frequent
site of skeletal metastasis [1], and radiotherapy (RT) is
the most common treatment option of bone metasta-
ses in an advanced tumour disease [2]. As a result of
the alteration in bone remodeling activity in patients
with bone metastases, various markers of bone forma-
tion or resorption have been investigated as a measure-
ment of activity of skeletal metastases. Balance
between bone resorption and bone formation is re-
quired for maintenance of bone metabolism, and can
be reflected by bone turnover markers (BTM). The
usefulness of BTM as a tool for the diagnosis of bone
metastases in many types of cancers has been investi-
gated previously [3]. Previous studies have demon-
strated that some BTM can indicate the existence of
* Correspondence: harald.rief@med.uni-heidelberg.de
1Department of Radiation Oncology, University Hospital of Heidelberg, Im
Neuenheimer Feld 400, 69120 Heidelberg, Germany
Full list of author information is available at the end of the article
© 2016 Rief et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rief et al. BMC Cancer  (2016) 16:231 
DOI 10.1186/s12885-016-2278-1
bone metastases [4], and have analyzed their relation-
ship with clinical outcomes [5–9].
The two most clinically relevant markers of bone
turnover in patients with skeletal metastases are bone-
specific alkaline phosphatase (BAP) and N-terminal telo-
peptide of collagen type I (NTX). Total amino-terminal
propeptide of type I collagen (PINP) and BAP are
markers of bone formation; BAP has a linear relation-
ship with osteoblast and osteoblastic precursor activity.
NTX is a breakdown product of type I collagen pro-
duced by various proteolytic enzymes during bone re-
sorption and dissolution of the organic bone matrix.
Additionally, pyridinium cross-links pyridinoline (PYD)
and desoxy-pyridinoline (DPD) are well-characterized
markers for bone resorption. C-terminal cross-linking
telopeptide of type I collagen (CTX-I) can be considered
a complementary tool for prediction of clinical outcome
as a marker of resorption. At the present time, although
biochemical markers of bone turnover have shown some
utility in clinical trials by predicting clinical outcomes
such as death or development of SREs, they are not
routinely used in clinical practice. Questions remain as
to how clinicians should best use these markers to select
and time appropriate treatments among patients with
bone metastases. The use of these markers may, in the
future, better allow physicians to selectively treat pa-
tients with bone metastases.
In our recent work, we could show the feasibility of re-
sistance training in patients with spinal bone metastases
under RT [10]. Importantly, we demonstrated that the
bone density in metastases of the resistance training arm
was significantly higher than in the control arm after
3 months. Therefore, we hypothesized that resistance
training concomitant to RT could influence bone metab-
olism, and would be reflected by BTM.
The aim of this randomized trial was to compare the
effect of resistance training concomitant to RT versus
RT only on BTM, such as BAP, PINP, CTX-I, PYD, DPD,
and NTX in patients with spinal bone metastases. Sec-
ondly, we evaluated an association of these markers as
predicted factors for local response, prevention of SRE,
and number of metastases.
Methods
Settings and patients
This is a randomized, controlled, two-armed interven-
tion trial. A block randomization approach with block
size 6 was used to ensure that the two intervention
groups were balanced. After the baseline measurements,
the patients with stable bone metastases were assigned
to the respective treatment groups on a 1:1 basis accord-
ing to the randomization list. Arm A (intervention
group, resistance training) and arm B (control group,
passive physical therapy) each consisted of 30 patients.
The blood and urine parameters were measured before
start of RT (t0) (day of the first fraction), and after three
months (t2) on an empty stomach. The primary endpoint
was to compare BTM after 3 months in patients treated
with resistance training concomitant to RT versus RT only
in spinal bone metastases. Secondary endpoint was to
evaluate predictive bone markers for local response, pre-
vention of SRE, and number of metastases. Local response
of metastasis was assessed on the basis of computed tom-
ography. Positive local response was defined as complete
or partial re-calcification on the basis of computed tomog-
raphy observation at 3 months after RT. The definition of
SRE was the first of any of the following events: patho-
logical fractures, severe pain (increase of more than 2
points according to numeric rating scale), hypercalcaemia,
and spinal cord compression. Number of metastases was
classified in 1 or >1 (solitary vs. multiple). The data of the
patient records were collected by the authors. Patient
characteristics are shown in Table 1.
Inclusion criteria were an age of 18 to 80 years, a
Karnofsky performance score [11] ≥ 70, written consent
to participate, and already initiated bisphosphonate
therapy. Patients were excluded if they presented with
concomitant pathologies that could interfere in the
evaluation of bone turnover markers, such as bone
metabolic disorders, Paget`s disease of bone, hyperpara-
thyroidism, thyroid abnormalities, abnormal intestinal
absorption, or hepatic or renal dysfunction. In all cases,
anticancer treatment could be changed as clinically indi-
cated throughout the course of the study. The patients
were subjected to a staging of their vertebral column
within the context of the computed tomography (CT)
designed to plan the radiation schedule prior to enrol-
ment into the trial. In this examination metastases were
classified as “stable” or “unstable”. This was diagnosed
independently by a specialist for radiology as well as by
a specialist for orthopedic surgery. The specifications for
an unstable vertebral body were tumor occupancy more
than 60 % of the vertebral body, and pedicle destruction
[12]. Only a metastasis classified by both specialists as
“stable” was suggested eligible for inclusion. Patients
with significant neurological or psychiatric disorders
were excluded. The study was approved by the Heidel-
berg Ethics Committee (Nr. S-316/2011).
Radiotherapy
RT was performed in the Radiooncology Department of
the Heidelberg University Clinic. After virtual simulation
was performed to plan the radiation schedule, RT was
carried out over a dorsal photon field of the 6MV energy
range. Primary target volume (PTV) covered the specific
vertebral body affected as well as the ones immediately
above and below. In Arm A, 24 patients (80 %) were
treated with 10 × 3 Gy, three patients (10 %) with 14 ×
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2.5 Gy, and three patients (10 %) with 20 × 2 Gy. In Arm
B the dose fractions for 28 patients (93.4 %) were 10 ×
3 Gy, for one patient (3.3 %) 14 × 2.5 Gy, and for one pa-
tient (3.3 %) 20 × 2 Gy. The median individual dose in
all patients was 3 Gy (range 2–3 Gy), the median total
dose 30 Gy (range 20–35 Gy). The individual and total
doses were decided separately for each individual
patient, depending on the histology, the patient’s general
state of health, and on the current staging and the corre-
sponding prognosis.
Study interventions
The interventions commenced on the same day as RT
and were performed on each day of RT treatment
Table 1 Patient characteristics at baseline
Intervention group (n = 30) Control group (n = 30)
n % n %
Age (years)
Mean (SD) 61.3 +/− 10.1 64.1 +/− 10.9
Gender
Male 14 46.7 19 63.3
Female 16 53.3 11 36.7
Karnofsky-index (median, range) 80 (70–100) 80 (70–100)
Primary site
Lung cancer 12 9.2 8 26.6
Breast cancer 5 16.7 6 20.1
Prostate cancer 5 16.7 9 30.1
Melanoma 1 3.3 1 3.3
Renal cancer 1 3.3 2 6.7
Other 6 20.1 4 13.4
Localization metastases
Thoracic 17 56.7 14 46.7
Lumbar 9 30.0 13 43.3
Thoracic and lumbar 2 6.7 2 6.7
Sacrum 2 6.7 1 3.3
Number metastases
Mean (range) 1.4 (2–4) 1.7 (1–5)
Solitary 22 73.3 18 60.0
Multiple 8 26.7 12 40.0
Type of metastases
osteoblast 9 30.0 10 33.3
osteolytic 21 70.0 20 66.7
Size of metastasis
Mean (SD) 318.6 +/− 230.0 380.7 +/− 193.6
Distant metastases at baseline
Visceral 12 40.0 5 16.7
brain 3 10.0 3 10.0
lung 7 23.3 4 13.3
tissue 8 26.7 6 20.0
Hormonotherapy 10 33.3 16 53.3
Immunotherapy 7 23.3 5 16.7
Chemotherapy 25 83.3 20 66.7
Previous SRE 9 30.0 13 43.3
Abbreviation: SD standard deviation
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(Monday through Friday) over a 2-week period, inde-
pendent of the number of fractions. During the 2-week
RT period, the patients in the resistance training arm
(Arm A) performed the exercises under the guidance of
a physiotherapist. The patients were then instructed to
practice the training in their homes three times a week
and continued the resistance training themselves until
the last investigation after three months, and conducted
the documentation in form of a training diary. The re-
sistance training lasted approx. 30 min, the passive phys-
ical therapy (Arm B) approx. 15 min. Since the site of
the bone metastases differed from patient to patient,
three different exercises were enacted to ensure an even
isometric resistance training of the paravertebral mus-
cles. Patients in the control arm (Arm B) received pas-
sive physical therapy in form of breathing exercises also
for a period of 2 weeks. This was conducted so that
these patients were not discouraged in comparison to
the intervention arm, and for avoidance of a high drop-
out rate. A detailed report of the intervention and its ap-
plication has already been published [13].
Statistical analysis
Bone marker values were presented in terms of mean
and standard deviation (SD). The possible difference be-
tween arms at 3 months was calculated using ANCOVA
with arm as factor and baseline value as covariate.
Therefore as all surviving patients completed all surveys
we assumed that 23 patients in Arm A and 24 patients
in Arm B were eligible for the analysis. Multivariate bin-
ary logistic regression models were fitted to quantify the
degree of association between potential predictors of
markers at baseline according to local response (yes/no),
prevention of SRE (yes/no), and number of metastases
(1/more than one). Group had been included as a covar-
iate in the analysis. Arm A with 23 survived patients was
the reference. Level of significance was set to 0.05 for all
tests. All statistical analyses were done using SAS soft-
ware Version 9.4 (SAS Institute, Cary, NC, USA).
Analytic methods
Samples were centrifuged at 3.500 rpm for 10 min after
drawing, serum obtained and stored at −80°. First morn-
ing void of urine was collected, mixed and an aliquot of
10 ml stored at – 80 °C. Samples shipped on dry ice to
the laboratory (Labor Limbach, Heidelberg, Germany)
and again stored at −80 °C until analysis.
Total aminoterminal propeptide of type I collagen
(PINP; bone formation; interassay coefficient of variation
[CV]: 2.7 %), C-terminal cross-linking telopeptide of type
I collagen (CTX-I; bone resorption; CV: 3.1 %) and intact
parathyroid hormone (iPTH; CV: 1.4 %) were measured
by means of an automated electrochemiluminescence
immunoassay (ECLIA; Modular Analytics E170, Roche
Diagnostics, Penzberg, Germany). Bone-specific alkaline
phosphatase (BAP; bone formation; CV: 5,2 %) was mea-
sured by means of a spectrophotometric immunoassay
(IDS-ISYS Ostase BAP; Immunodiagnostic Systems Ltd
[IDS Ltd], Boldon, Tyne & Wear, UK) on the fully auto-
mated immunoassay system (IDS-ISYS (Immunodiagnos-
tic Systems Ltd [IDS Ltd], Boldon, Tyne & Wear, UK).
Pyridinoline (PYD) and deoxypyridinoline (DPD; bone
resorption; CV: 12.5 %) were assayed by high performance
liquid chromatography (HPLC) [14, 15]. Analysis required
first a sample extraction, hydrolysis and automated
column-chromatographic pre-purification. To avoid any
effect of different dilutions of urine, Pyr and Dpyr data are
expressed against gram of creatinine. Cross-linked N-
telopeptides of type I collagen (NTx; bone resorption; CV:
12.8 %) was determined with an commercially available
ELISA (Osteomark Ntx; Wampole Laboratories, Princeton
NJ, USA).
All laboratory analyses were done in two batches after
completion of the sample collection. To further reduce
imprecision of measurement, all samples were analyzed
utilizing one reagent lot. Tests and instruments were
run strictly in accordance with the guidelines given by
the manufacturer and were subject to continuous main-
tenance and service according to the laboratories stand-
ard operating procedures for good laboratory practice.
Samples were thawed at the day of analysis at ambient
temperature, mixed on a head-over-head mixer and cen-
trifuged before measurement.
Results
From September 2011 to March 2013, consecutive 80
patients with a histologically confirmed cancer of any
primary and spinal bone metastases of the thoracic or
lumbar segments, or of the sacral region were consid-
ered in the Radiooncology Department of the Heidelberg
University Clinic. Fifteen patients were excluded due to
unstable metastases, and five patients declined to partici-
pate in the study. Sixty patients fulfilled the inclusion
and were enrolled into the trial (Fig. 1). Arms were bal-
anced at baseline without group differences, particularly
number of metastases and tumor size (Table 1). Seven
patients (23.3 %) died in arm A within the first 12 weeks
following RT, six patients in arm B (20.0 %) died within
3 months. The mean follow-up was 3.3 months for both
groups. All surviving patients completed all surveys.
Mortality did not differ between groups.
Mean change values of PYD and CTX-I were signifi-
cantly lower at 3 months after RT (p = 0.035 and p =
0.043) in arm A. DPD showed a tendency with a lower
mean change value, but not significant. No changes were
seen between the arms in BAP, NTX, and PINP. Import-
antly, all markers decreased in both arms, except of PYD
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and CTX-I in arm B, although significance was not
reached for some biomarkers (Table 2).
In arm A, the local response was significantly higher
[73.9 % (n = 17) vs. 25 % (n = 6)] (p = 0.003). At first, PINP
could be identified as a predictor of local response (p =
0.043). BAP (p = 0.034) and PINP (p = 0.044) could be
identified as a predictor for avoidance of SRE. No marker
could be detected for solitary metastasis (Table 3).
Discussion
Bone metastases are a very frequent secondary diagnosis
associated with an advanced tumor disease, with the ver-
tebral column being the most frequent localization [2,
10]. The usefulness of BTM as tool for the diagnosis of
bone metastases in many types of cancers has been in-
vestigated previously [3]. Many studies have analyzed
their relationship with clinical outcomes [7, 16] as well
as their clinical importance [17, 18]. However, there is
still no concensus among these studies as to which BTM
is the ideal marker.
In the current work, all BTM in arm A decreased after
3 months, especially the mean change values of PYD
and CTX-I were significantly lower at 3 months after RT
due to resistance training. BTM in arm B showed also
decreased values after 3 months except of PYD and
CTX-I, but not so distinctive as in arm A. Importantly,
local response as re-calcification in metastasis was im-
proved in arm A due to resistance training. In our recent
work, we could show that bone density was significantly
increased in metastasis 3 months after start of resistance
training concomitant to RT [19]. This factor may influ-
ence the BTM and was demonstrated in our results.
Therefore, PINP could be detected as a strong marker
for bone formation after combined treatment with resist-
ance training concomitant to RT.
Determination of CTX-I is recommended for monitor-
ing the efficacy of antiresorptive therapy. Patients with
renal cell carcinoma who died or progressed had higher
baseline B-CTX levels and those who experienced SRE
during follow-up showed high BAP levels [20]. However,
in our results we could not found any useful data in nor-
mal/abnormal values of BTM. A multicenter study
found that increased values of BAP and NTX were asso-
ciated with increased risk of SRE, and disease progres-
sion in patients with breast cancer, prostate cancer, and
other solid tumors, treated with bisphosphonates [21].
These markers of bone turnover have been used clinic-
ally to predict the risk of SREs and disease outcomes.
According our results, we could identify BAP and PINP
for avoidance of SRE. In addition, biochemical markers
of bone turnover may prove useful in the monitoring of
patients on bisphosphonate treatment for bone metasta-
ses. One review [22] of 121 patients with skeletal metas-
tases from variety of solid tumors revealed that mean
values of NTX were consistently elevated in patients ex-
periencing SREs compared with those who did not. An
additional study [23] showed in 441 patients that pa-
tients with high NTX or BAP levels had a greater inci-
dence of SREs compared with patients with low levels of
NTX or BAP. Patients with increased NTX or BAP at
80 patients screened
15 unstable metastases
5 patients rejected trial
60 patients enrolled with 
stable metastases
30 randomly assigned to 
intervention group 
30 randomly assigned to 
control group 
30 completed assisted 
intervention
23 completed 12 week 
follow-up in intervention 
group
30 completed control 
group
24 completed 12 week 
follow-up in control group
Fig. 1 Flow of participants through the trial
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baseline had an increased risk for SRE, shorter time to
first event, disease progression and death. As NTX levels
have been shown to correlate with response to bisphos-
phonate treatment. In our data, we could not show any
correlation of NTX to local response, SRE, and number
of metastases, but we were able to confirm the relation
to BAP with prevention of SRE. Zoledronic acid normal-
izes or maintains normal NTX levels in most patients
with bone metastases. All of our participants were
treated with bisphosphonates. Our data presented no
differences between arms of NTX.
However, a PINP could be identified as a predictor for
local response and avoidance of SRE. In this novel study,
our results showed that resistance training concomitant
to RT can even enhance an effect on BTM.
Since all patients were in advanced stages of their can-
cer, 40 % of the patients in either group were lost to
follow-up due to progressive disease and subsequently
death. Further limitations of the study were the relatively
small sample size, the variety of primary tumors and pa-
tient conditions, and the exclusion of patients presenting
with cervical spine metastases.
Among the strengths of our novel and original study
were the randomized design and the very first presenta-
tion of bone turnover markers in combined treatment of
resistance training concomitant to RT in patients with
spinal bone metastases.
Conclusion
In this group of patients with spinal bone metastases, we
were able to show that patients with guided resistance
training of the paravertebral muscles can influence
BTM. PYD and CTX-I decreased significantly in arm A.
PINP can be considered as a complementary tool for
prediction of local response, and PINP as well as BAP
for avoidance of SRE. More studies in larger groups of
patients are necessary for further confirmatory research.
Ethics approval
The study was approved by the Heidelberg Ethics Com-
mittee (Nr. S-316/2011).
Consent for publication
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Table 2 Results of bone turnover markers
Arm A Arm B Difference between arms
baseline, n=23 3 months, n=23 baseline, n=24 3 months, n=24 LS means
Parameter Reference value mean SD mean SD mean SD mean SD Difference (95 % CI) p-value*
PYD 160–280 μg/g Cr 375.63 206.20 299.89 173.88 402.00 199.01 405.50 187.32 −90.92 (−175.19; −6.65) 0.035
DPD 26–65 μg/g Cr 67.30 39.64 51.20 35.81 86.10 78.85 72.88 37.11 −18.20 (−38.84; 2.45) 0.082
CTX-I <0.5484 ng/ml 0.29 0.27 0.20 0.23 0.39 0.37 0.42 0.45 −0.10 (−0.20; −0.003)) 0.043
BAP 6–15 μg/l 56.89 92.31 31.46 63.31 44.17 47.32 36.52 37.58 −12.10 (−31.51; 7.31) 0.215
NTX 5.4–24.2 nmol/l 19.09 7.21 17.42 7.98 21.42 9.36 20.38 9.81 −0.87 (−3.84; 2.10) 0.556
PINP 15–59 μg/l 67.54 40.69 49.50 41.43 87.96 51.98 66.77 39.18 −6.94 (−26.81; 12.93) 0.485
*Results of ANCOVA
This table shows the results of bone turnover markers of both groups at baseline and 3 months after RT. Differences are presented within and between groups
Abbreviation: LS means least square means
Table 3 Results of multivariate binary logistic regression analysis
of bone markers
Local response (no local response) OR 95 % CI (OR) p-value
Arm (A – reference) 0.033 0.004 – 0.311 0.003
PYD 1.000 0.992 – 1.008 0.986
DPD 1.023 0.974 – 1.074 0.371
CTX-I 10.550 0.003 – >100 0.569
BAP 1.011 0.996 – 1.025 0.142
NTX 0.870 0.688 – 1.101 0.245
PINP 0.968 0.938 – 0.999 0.043
Prevention of SRE (SRE = 0) OR 95 % CI (OR) p-value
Arm (A – reference) 3.302 0.877 – 12.431 0.077
PYD 0.998 0.994 – 1.002 0.373
DPD 1.006 0.982 – 1.031 0.633
CTX-I 0.323 0.001 – 81.336 0.689
BAP 0.974 0.950 – 0.998 0.034
NTX 0.988 0.861 – 1.134 0.865
PINP 1.025 1.001 – 1.049 0.044
Solitary metastasis (n = 1) OR 95 % CI (OR) p-value
Arm (A – reference) 1.692 0.477 – 6.007 0.416
PYD 1.001 0.997 – 1.005 0.512
DPD 1.004 0.980 – 1.029 0.761
CTX-I 0.359 0.001 – >100 0.723
BAP 0.997 0.985 – 1.009 0.592
NTX 1.083 0.939 – 1.249 0.275
PINP 0.998 0.981 – 1.016 0.829
Abbreviation: SRE skeletal-related events
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